NCT02334436View on ClinicalTrials.gov

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

PHASE3CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Botulinum toxin, Type A

Botulinum toxin, Type A

OTHER

0.9% sterile, unpreserved saline

Placebo Comparator Arm

Trial Locations (1)

90210

The Clinical Testing Center of Beverly Hills, Beverly Hills

Sponsors

Lead Sponsor

Evolus, Inc.

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Evolus, Inc.

INDUSTRY